Skip to main content
SpringerLink
Log in

An Overview of the Clinical Evaluation of Lymphomas According to the WHO 2008 Classification

  • Chapter
  • First Online:
PET/CT in Lymphomas

  • 1084 Accesses

Abstract

Malignant lymphomas are neoplasms of the lymphoid tissue, which are divided into Hodgkin (HL) and non-Hodgkin lymphomas (NHL). They are classified according to the 2008 World Health Organization (WHO) scheme [1], using clinical, morphologic, immunophenotypic, and genetic features to define distinct entities (Table 1.1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Swerdlow SH, Campo E (2008) WHO classification: pathology and genetics of tumors of haematopoietic and lymphoid tissues. IARC Press, Lyon

    Google Scholar 

  2. Hartge P, Wang SS, Bracci PM, Devesa SS, Holly EA (2006) Non-Hodgkin lymphoma. In: Schottenfeld D, Fraumeni JFJ (eds) Cancer epidemiology and prevention, 3rd edn. Oxford University Press, New York, pp 898–918

    Chapter  Google Scholar 

  3. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225

    Article  PubMed  Google Scholar 

  4. Chiu BC, Weisenburger DD (2003) An update of the epidemiology of non-Hodgkin’s lymphoma. Clin Lymphoma 4(3):161–168

    Article  PubMed  Google Scholar 

  5. D’Addario G, Dieterle A, Torhorst J et al (2003) HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration study. Leuk Lymphoma 44:133

    Article  PubMed  Google Scholar 

  6. National Comprehensive Cancer Network (NCCN) (2014) NCCN Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 01 April 2014

  7. Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3067

    Article  PubMed  Google Scholar 

  8. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the Committee on Hodgkin’s disease staging classification. Cancer Res 31:1860–1861

    CAS  PubMed  Google Scholar 

  9. Barrington SF, Mikhaeel NG, Kostakoglu L et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32:3048

    Article  PubMed  Google Scholar 

  10. Conlan MG, Bast M, Armitage JO, Weisenburger DD (1990) Bone marrow involvement by non-Hodgkin’s lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 8:1163

    CAS  PubMed  Google Scholar 

  11. Foucar K, McKenna RW, Frizzera G, Brunning RD (1982) Bone marrow and blood involvement by lymphoma in relationship to the Lueks-Collins classification. Cancer 49:888

    Article  CAS  PubMed  Google Scholar 

  12. Savage KJ, Zeynalova S, Kansara RR et al (2014) Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. Blood (ASH Annual Meeting Abstracts) 124:394

    Google Scholar 

  13. Hedge U, Filie A, Little RF et al (2005) High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 105:496

    Article  Google Scholar 

  14. Aw L, Mangu PB, Beck LN et al (2013) Fertility preservation for patients with cancer. American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:2500

    Article  Google Scholar 

  15. Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571

    Article  PubMed  Google Scholar 

  16. Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752

    Article  CAS  PubMed  Google Scholar 

  17. Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglou L, Gregianin M et al (2014) The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 99:1107–1113

    Article  PubMed  PubMed Central  Google Scholar 

  18. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M et al (2014) The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165:112–116

    Article  CAS  PubMed  Google Scholar 

  19. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 43:1018–1027

    PubMed  Google Scholar 

  20. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T et al (2002) Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 13(9):1356–1363

    Article  CAS  PubMed  Google Scholar 

  21. Horning SJ, Juweid ME, Schoeder H et al (2010) Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood 115:775–777

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Casasnovas RO, Meignan M, Berriolo-Riedinger A et al (2011) SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 118:37–43

    Article  CAS  PubMed  Google Scholar 

  23. Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, Verra P et al (2013) An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax. Eur J Nucl Med Mol Imaging 40:1312–1320

    Article  PubMed  Google Scholar 

  24. Moskowitz C, Matasar MJ, Zelenetz AD et al (2012) Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 119(7):1665–1670

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Schot B, van Imhoff G, Pruim J et al (2003) Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol 123:282

    Article  PubMed  Google Scholar 

  26. Sauter CS, Matasar MJ, Meikle J et al (2015) Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood 125(16):2579–2581

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Derenzini E, Musuraca G, Fanti S et al (2008) Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer 113:2496

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Athens Hematology Clinic, G.N.A. “POP”, St. Thomas 17, Athens, 11527, Greece

    Theodoros P. Vassilakopoulos

  2. Hygeia Hospital, 4 Erythrou Stavrou Street and Kifisias Avenue, Athens, 15123, Greece

    Effimia P. Vrakidou

Authors
  1. Theodoros P. Vassilakopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Effimia P. Vrakidou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Theodoros P. Vassilakopoulos .

Editor information

Editors and Affiliations

  1. Hygeia and Mitera Hospital, Athens, Greece

    John A. Andreou

  2. Hygeia Hospital, Medical Oncology Department, Athens, Greece

    Paris A. Kosmidis

  3. National & Kapodistrian University, Radiology (emeritus), Athens, Greece

    Athanasios D. Gouliamos

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Vassilakopoulos, T.P., Vrakidou, E.P. (2016). An Overview of the Clinical Evaluation of Lymphomas According to the WHO 2008 Classification. In: Andreou, J., Kosmidis, P., Gouliamos, A. (eds) PET/CT in Lymphomas. Springer, Cham. https://doi.org/10.1007/978-3-319-27380-8_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-27380-8_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-27378-5

  • Online ISBN: 978-3-319-27380-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation